依达拉奉联合奥扎格雷钠治疗急性脑梗死疗效及安全性探讨.docVIP

依达拉奉联合奥扎格雷钠治疗急性脑梗死的疗效及安全性探讨 　　[摘要] 目的 针对急性脑梗死病症，采用依达拉奉联合奥扎格雷钠进行治疗，探讨其疗效与安全性。方法 临床纳入急性脑梗死患者70例，根据治疗方法的不同分为研究组与对照组。研究组给予依达拉奉联合奥扎格雷钠，对照组仅给予奥扎格雷钠。对两组患者分别进行严密观察，查看治疗后的效果，即疗效，患者日常的生活能力指数评分和神经功能的缺损评分在治疗前后分别对其进行对比分析。此外，观察患者治疗期间发生的药物不良反应。结果 研究组治疗有效率为97.14%，对照组治疗有效率为82.86%，差异有统计学意义（P0.05）；研究组治疗后第2、4周神经功能缺损评分为（16.33±10.57）、（13.10±9.11），对照组为（21.20±13.20）、（18.60±10.21）；研究组治疗后第2、4周日常生活能力指数评分为（50.20±15.22）、（66.03±16.11），对照组为（42.57±13.63）、（52.25±14.01），差异均有有统计学意义（P0.05）；两组患者治疗期间均未出现药物不良反应。结论 依达拉奉联合奥扎格雷钠治疗急性脑梗死的疗效确切，能够短期内促进神经功能的恢复，且无明显的不良反应，值得推广。 　　[关键词] 依达拉奉；奥扎格雷钠；急性脑梗死；疗效；安全性 　　[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2014）11（c）-0040-03 　　[Abstract] Objective To observe the effect and safety of edaravone combined with sodium ozagrel in the treatment of acute cerebral infarction. Methods 70 cases with acute cerebral infarction were enrolled clinically and divided into the study group and the control group according to different treatment methods. The study group was treated by edaravone combined with sodium ozagrel， and the control group was treated by sodium ozagrel. Two groups of patients were observed intensively for checking the treatment effect， namely， the efficacy. The activity of daily living and neurological deficit score of both groups were compared and analyzed before and after treatment. In addition， the adverse drug reactions occurred in both groups during the treatment were observed. Results The effective rate of the study group was 97.14%， and that of the control group was 82.86%， the difference was significant （P0.05）； the neurological deficit score of the study group after 2 weeks and 4 weeks of treatment was （16.33±10.57） points， （13.10±9.11） points， respectively， and that of the control group was （21.20±13.20） points， （18.60±10.21） points， respectively； the score of activity of daily living of the study group after 2 weeks and 4 weeks of treatment was （50.20±15.22） points， （66.03±16.11） points， respectively， and that of the control group was （42.57±13.63） point